• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝 FXR:全身能量代谢的关键调节因子。

Hepatic FXR: key regulator of whole-body energy metabolism.

机构信息

Center for Neurosciences and Cell Biology, MitoLab, Department of Life Sciences, University of Coimbra, Coimbra, Portugal.

出版信息

Trends Endocrinol Metab. 2011 Nov;22(11):458-66. doi: 10.1016/j.tem.2011.07.002. Epub 2011 Aug 19.

DOI:10.1016/j.tem.2011.07.002
PMID:21862343
Abstract

The farnesoid X receptor (FXR) is a nuclear receptor whose activation leads to alterations in pathways involved in energy metabolism. For example, it serves as a bile acid receptor in tissues such as the liver, and as an energy metabolism regulator in liver, muscle and adipose tissue. However, the effects of FXR activation are not exclusive to the tissue where it is present, because receptor crosstalk affects tissues throughout the body. It has been demonstrated that FXR regulates the metabolism of not just bile acids, but also of fats and hydrocarbon metabolites. FXR is currently under study as a therapeutic target for the treatment of diseases of excess, such as diabetes. Here we review the effects of FXR activation in the response of an organism to excess energy.

摘要

法尼醇 X 受体(FXR)是一种核受体,其激活会导致能量代谢相关途径的改变。例如,它在肝脏等组织中作为胆汁酸受体,在肝脏、肌肉和脂肪组织中作为能量代谢调节剂。然而,FXR 激活的作用不仅限于其存在的组织,因为受体串扰会影响全身的组织。已经证明,FXR 不仅调节胆汁酸的代谢,还调节脂肪和碳氢化合物代谢物的代谢。FXR 目前正在作为治疗过度疾病(如糖尿病)的治疗靶点进行研究。在这里,我们综述了 FXR 激活对机体应对能量过剩的影响。

相似文献

1
Hepatic FXR: key regulator of whole-body energy metabolism.肝 FXR:全身能量代谢的关键调节因子。
Trends Endocrinol Metab. 2011 Nov;22(11):458-66. doi: 10.1016/j.tem.2011.07.002. Epub 2011 Aug 19.
2
Role of bile acids and bile acid receptors in metabolic regulation.胆汁酸及胆汁酸受体在代谢调节中的作用
Physiol Rev. 2009 Jan;89(1):147-91. doi: 10.1152/physrev.00010.2008.
3
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.法尼醇是甲羟戊酸途径的一种中间体,它通过法尼酯X受体介导的雌激素受体激活来刺激MCF-7乳腺癌细胞的生长。
Breast Cancer Res Treat. 2008 Jan;107(1):49-61. doi: 10.1007/s10549-007-9535-6. Epub 2007 Feb 28.
4
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.法尼醇X受体(FXR)作为非酒精性脂肪性肝炎的新靶点。
Diabetes Metab. 2008 Dec;34(6 Pt 2):685-91. doi: 10.1016/S1262-3636(08)74605-6.
5
Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways.法呢醇,一种异戊二烯,通过 PPARα 依赖和非依赖途径改善小鼠的代谢异常。
Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E1022-32. doi: 10.1152/ajpendo.00061.2011. Epub 2011 Aug 23.
6
FXR, a multipurpose nuclear receptor.法尼酯X受体(FXR),一种多功能核受体。
Trends Biochem Sci. 2006 Oct;31(10):572-80. doi: 10.1016/j.tibs.2006.08.002. Epub 2006 Aug 14.
7
The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.法尼酯X受体:胆汁酸与脂质及葡萄糖代谢之间的分子联系。
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2020-30. doi: 10.1161/01.ATV.0000178994.21828.a7. Epub 2005 Jul 21.
8
Targeting farnesoid X receptor for liver and metabolic disorders.以法尼醇X受体为靶点治疗肝脏和代谢紊乱疾病。
Trends Mol Med. 2007 Jul;13(7):298-309. doi: 10.1016/j.molmed.2007.06.001. Epub 2007 Jun 27.
9
Farnesoid X receptor: A "homeostat" for hepatic nutrient metabolism.法尼醇 X 受体:肝脏营养代谢的“稳态调节因子”。
Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):45-59. doi: 10.1016/j.bbadis.2017.10.003. Epub 2017 Oct 3.
10
Farnesoid X receptor as a regulator of fuel consumption and mitochondrial function.法尼醇 X 受体作为燃料消耗和线粒体功能的调节剂。
Arch Pharm Res. 2016 Aug;39(8):1062-74. doi: 10.1007/s12272-016-0812-y. Epub 2016 Aug 11.

引用本文的文献

1
Bile acid receptors regulate the role of intestinal macrophages in inflammatory bowel disease.胆汁酸受体调节肠道巨噬细胞在炎症性肠病中的作用。
Front Immunol. 2025 Jun 17;16:1577000. doi: 10.3389/fimmu.2025.1577000. eCollection 2025.
2
Targeting Bile-Acid Metabolism: Nutritional and Microbial Approaches to Alleviate Ulcerative Colitis.靶向胆汁酸代谢:缓解溃疡性结肠炎的营养和微生物学方法
Nutrients. 2025 Mar 28;17(7):1174. doi: 10.3390/nu17071174.
3
Gut Microbiota and Their Metabolites: The Hidden Driver of Diabetic Nephropathy? Unveiling Gut Microbe's Role in DN.
肠道微生物群及其代谢产物:糖尿病肾病的隐藏驱动因素?揭示肠道微生物在糖尿病肾病中的作用。
J Diabetes. 2025 Apr;17(4):e70068. doi: 10.1111/1753-0407.70068.
4
Evaluation of FXR Activity in Pollutants Identified in Sewage Sludge and Subsequent and Characterization of Metabolic Effects of Triphenyl Phosphate.污水污泥中鉴定出的污染物中法尼醇X受体(FXR)活性评估及磷酸三苯酯代谢效应的表征
Environ Health Perspect. 2025 Apr;133(3-4):47005. doi: 10.1289/EHP15435. Epub 2025 Apr 14.
5
Farnesoid X receptor (FXR) as a potential therapeutic target for lung diseases: a narrative review.法尼酯X受体(FXR)作为肺部疾病的潜在治疗靶点:一篇叙述性综述
J Thorac Dis. 2024 Nov 30;16(11):8026-8038. doi: 10.21037/jtd-24-734. Epub 2024 Nov 29.
6
HSDL2 links nutritional cues to bile acid and cholesterol homeostasis.HSDL2 将营养线索与胆汁酸和胆固醇的体内平衡联系起来。
Sci Adv. 2024 May 31;10(22):eadk9681. doi: 10.1126/sciadv.adk9681.
7
Enhancing growth, liver health, and bile acid metabolism of tilapia () through combined cholesterol and bile acid supplementation in plant-based diets.通过在植物性饲料中联合添加胆固醇和胆汁酸来促进罗非鱼的生长、肝脏健康和胆汁酸代谢。
Anim Nutr. 2024 Mar 8;17:335-346. doi: 10.1016/j.aninu.2024.03.001. eCollection 2024 Jun.
8
A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment.一种针对法尼醇X受体、铁死亡和纤维化的联合纳米治疗方法用于非酒精性脂肪性肝炎的治疗。
Acta Pharm Sin B. 2024 May;14(5):2228-2246. doi: 10.1016/j.apsb.2024.02.017. Epub 2024 Feb 26.
9
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice.微生物代谢产物胍丁胺作为 FXR 激动剂促进雌性小鼠多囊卵巢综合征。
Nat Metab. 2024 May;6(5):947-962. doi: 10.1038/s42255-024-01041-8. Epub 2024 May 20.
10
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.当前治疗肝纤维化的研究:在重新利用 FDA 批准的药物和其他新兴方法之间。
J Pharm Pharm Sci. 2023 Nov 7;26:11808. doi: 10.3389/jpps.2023.11808. eCollection 2023.